Aurinia Pharmaceuticals (NASDAQ:AUPH) Issues Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Aurinia Pharmaceuticals reported an earnings per share (EPS) of $0.16, missing analysts' expectations of $0.17 by $0.01.
• The company achieved revenues of $70.01 million for the quarter, exceeding analyst estimates of $64.27 million.
• Several institutional investors have increased their stakes, including AQR Capital Management, which boosted its position by 8.7% in the first quarter.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP issued its quarterly earnings data on Thursday. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01), Zacks reports. The business had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Stock Down 0.8%

AUPH stock traded down $0.09 during midday trading on Wednesday, hitting $11.61. The company's stock had a trading volume of 3,849,019 shares, compared to its average volume of 1,589,323. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. Aurinia Pharmaceuticals has a twelve month low of $5.25 and a twelve month high of $11.80. The company's fifty day moving average price is $8.49 and its 200 day moving average price is $8.18. The stock has a market capitalization of $1.53 billion, a P/E ratio of 27.00 and a beta of 1.23.

Insider Transactions at Aurinia Pharmaceuticals

In other news, Director Kevin Tang acquired 200,000 shares of the stock in a transaction dated Tuesday, August 5th. The shares were bought at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the purchase, the director directly owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have acquired 1,300,000 shares of company stock valued at $13,590,000. 12.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AUPH. Royal Bank of Canada boosted its holdings in Aurinia Pharmaceuticals by 65.3% in the 1st quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company's stock valued at $2,956,000 after purchasing an additional 145,179 shares during the period. AQR Capital Management LLC boosted its holdings in Aurinia Pharmaceuticals by 8.7% in the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company's stock valued at $4,048,000 after purchasing an additional 40,380 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Aurinia Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company's stock valued at $642,000 after purchasing an additional 3,497 shares during the period. Institutional investors and hedge funds own 36.83% of the company's stock.

Analysts Set New Price Targets

AUPH has been the topic of several recent analyst reports. Royal Bank Of Canada boosted their target price on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. HC Wainwright restated a "buy" rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.